Skip to main content
Premium Trial:

Request an Annual Quote

Iconix to Perform Chemogenomic Profiling for Neurocrine

NEW YORK, July 12 (GenomeWeb News) - Iconix Pharmaceuticals will provide Neurocrine Biosciences with chemogenomic analyses on candidate compounds in Neurocrine drug-discovery programs, Iconix said today.

 

As part of the agreement, Iconix's DrugMatrix technology will be used to provide a gene expression-based chemogenomic work-up on a minimum of 12 Neurocrine compounds.

 

Iconix will then provide summary analyses to Neurocrine that will include analysis of on- and off-target effects including toxicity as revealed by gene-expression profiles, as well as the impact of the gene-expression changes on critical biological pathways and Iconix's DrugSignatures biomarker information, Iconix said.

 

Financial terms of the agreement were not disclosed.

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.